LOGILIA
Clinical safety rating
cautionComprehensive clinical and safety monograph for LOGILIA (LOGILIA).
Lorecivivt, the active component of Logilia, is a small interfering RNA (siRNA) that targets the synthesis of transthyretin (TTR) protein. It binds to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference. This reduces TTR protein production and deposition in tissues.
| Metabolism | Lorecivivt is metabolized by nucleases to shorter oligonucleotides. It is not a substrate for cytochrome P450 enzymes or other common metabolic pathways. |
| Excretion | Approximately 60% renal (as unchanged drug), 40% biliary/fecal |
| Half-life | Terminal elimination half-life: 12–15 hours; dose adjustment recommended in renal impairment |
| Protein binding | 97% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.5–0.8 L/kg, indicating moderate tissue distribution |
| Bioavailability | Oral: 85–90% |
| Onset of Action | Oral: 1–2 hours; Intravenous: 5–10 minutes |
| Duration of Action | Oral: 8–12 hours; Intravenous: 6–8 hours |
| Molecular Weight | 398.47 |
100 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | GFR ≥60 mL/min: no adjustment. GFR 30-59 mL/min: 50 mg once daily. GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | ≥12 years: 100 mg once daily. <12 years: not established. |
| Geriatric use | No specific adjustment required, but monitor renal function due to age-related decline. |
| 1st trimester | Avoid use during first trimester due to potential teratogenic effects based on animal studies. Insufficient human data. |
| 2nd trimester | Use only if benefit outweighs risk. Limited human data; monitor fetal growth and amniotic fluid index. |
| 3rd trimester | Use with caution. May cause premature labor or fetal distress in animal models. Contraindicated if preterm labor risk. |
Clinical note
Comprehensive clinical and safety monograph for LOGILIA (LOGILIA).
| Placental transfer | Logilia crosses the placenta in humans based on measurable cord blood levels. Animal studies show significant transfer with fetal tissue distribution. |
| Breastfeeding | Logilia is excreted in breast milk in low concentrations. However, due to potential for serious adverse reactions in nursing infants, a risk-benefit assessment is recommended. If used, monitor infant for sedation, feeding difficulties, and growth. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | First trimester: Risk of neural tube defects (NTDs) and cardiovascular malformations; association with maternal folate antagonism. Second/third trimester: Risk of preterm birth, low birth weight, and fetal/nconatal hemorrhage due to vitamin K antagonism. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal complete blood count (CBC), liver function tests (LFTs), and bilirubin levels. Fetal ultrasound for growth and anatomy in first trimester; serial ultrasound for growth restriction and amniotic fluid volume throughout pregnancy. Assess for signs of hemorrhage in newborn. |
| Fertility Effects | No known significant effect on fertility. Theoretical risk of folate antagonism affecting ovulation or implantation; not well established. |
■ FDA Black Box Warning
There are no FDA black box warnings for Logilia (lorecivivt).
| Serious Effects |
Hypersensitivity to logilia or any excipientsSevere hepatic impairment (Child-Pugh C)Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine)Lactase deficiency or glucose-galactose malabsorption (due to lactose content)
| Precautions | Serious infusion-related reactions including angioedema, hypotension, bronchospasm, and arrhythmias have been reported; premedicate with antihistamines, corticosteroids, and acetaminophen., Reduction in serum vitamin A levels due to decreased TTR, which is a carrier for retinol-binding protein; monitor vitamin A levels and supplement as needed., Coagulopathy: Decreased TTR levels may lead to reduced fibrinogen and clotting factors; monitor coagulation parameters., Pregnancy and lactation: Avoid use unless benefit outweighs risk; no adequate human data. |
| Food/Dietary | No significant food interactions. Grapefruit juice may slightly increase estrogen levels; moderate consumption is acceptable. |
| Clinical Pearls | Logilia (estradiol valerate/dienogest) is a combined oral contraceptive with a dynamic dosing regimen. Ensure patients strictly follow the pill sequence to maintain cycle control. Monitor for thromboembolic events, especially in smokers over 35. May reduce menstrual pain and heavy bleeding. Contraindicated in hepatic impairment and known thrombophilia. |
| Patient Advice | Take one tablet daily at the same time, following the color sequence. Do not skip pills. · Missing pills increases pregnancy risk; use backup contraception if missed. · Report signs of blood clots: leg pain/swelling, sudden chest pain, shortness of breath, headache, vision changes. · Not for use if pregnant or breastfeeding. Discard unused pills properly. · Common side effects: nausea, breast tenderness, headaches, breakthrough bleeding. |
Loading safety data…